Dicer-substrate

Dicerna Pharmaceuticals this week announced the publication of data by company researchers and collaborators demonstrating the potential therapeutic benefit of knocking down a key cancer target using RNAi.

Dicerna Pharmaceuticals this week announced that partner Kyowa Hakko Kirin has decided to advance a second cancer drug candidate into formal development as part of the companies' ongoing alliance.
The move has triggered a $5 million milestone payment to Dicerna.

Dicerna Pharmaceuticals said this week that it has reached another milestone in its collaboration with Kyowa Hakko Kirin after the Japanese pharmaceutical firm “recognized the successful achievement of an in vivo activity milestone” for a second oncology drug candidate.

LAS VEGAS — Dicerna Pharmaceuticals has selected a target and delivery technology for its first drug candidate, and remains on track to meet its previously stated goal of filing an investigational new drug application by the end of 2013, a company official disclosed this week.

Dicerna Pharmaceuticals announced this week that it has earned a $5 million milestone payment after partner Kyowa Hakko Kirin decided to further develop an oncology drug candidate covered by the companies' drug-development alliance.

Dicerna Pharmaceuticals said this week that the US Patent and Trademark Office has issued the company a notice of allowance for a patent application covering its core Dicer-substrate technology.

Dicerna recently announced that its CEO had stepped down and will be replaced by company Co-Founder Doug Fambrough. He was a general partner at VC firm Oxford Bioscience Partners, an early investor in Sirna Therapeutics.

Under the terms of the arrangement, Dicerna will receive from Kyowa $4 million up front and up to $120 million in research funding and milestones in exchange for the exclusive rights to an undisclosed cancer target. Additional targets may be added to the arrangement under similar terms.

Strands

Premium

MDRNA, Roche, Arrowhead Research, Rosetta Genomics, Alnylam Pharmaceuticals, Genesis Research and Development

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.